Sanofi looking at 1-2 bn euros of acquisitions per year

French pharmaceutical group Sanofi is looking to make annual acquisitions of up to two billion euros to boost its priority sectors, managing director Chris Viehbacher told Monday's Le Figaro newspaper.

"We are going to keep reinforcing the growth platforms to a tune of one to two billion euros ($1.4-2.7 billion) a year in acquisitions," he said.

The designated areas are diabetes treatment, vaccines, , self-medication, emerging markets, and "other ," he said.

The announced strategy comes after Sanofi last month downgraded its full-year outlook because of falling sales due to end of some exclusive patent rights in August.

Viehbacher told Le Figaro that two-thirds of Sanofi's research budget now went to biotechnological treatments difficult to copy.

"There is therefore little risk" of encountering the same patent-loss problem, he said.

In the interview, Viehbacher made no mention of a brewing legal case over Gardasil, a Sanofi vaccine that combats uterine cancer.

An 18-year-old Frenchwoman last Friday lodged a criminal complaint claiming the vaccine had side-effects resulted in an inflammation of her nervous system.

A Paris legal firm said another three women planned to lodge other complaints within the next two weeks after suffering different problems.

Explore further

Sanofi says profits hit by patent expiry, vaccine problems

© 2013 AFP

Citation: Sanofi looking at 1-2 bn euros of acquisitions per year (2013, November 25) retrieved 23 September 2019 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more